Ionis Pharmaceuticals News About ALS Treatment Attempts

Ionis Pharmaceuticals Dosed First Patients with ION541 for ALS

Ionis Pharmaceuticals (IONS) announced that the first patients have been dosed with ION541 (also known as BIIB105) – an investigational antisense medicine being developed as a potential therapy to treat most forms of amyotrophic lateral sclerosis (ALS), regardless of family history. This is another milestone in the continuing progress of Ionis’ ambitious program to develop novel treatments for ALS.

Leave a Reply